Cargando…

Case Report: Pseudoprogression With Nivolumab and Bevacizumab Followed by Recurrent Immune-Related Pneumonitis in Urothelial Carcinoma With Lung Metastasis

BACKGROUND: Combination therapy with immune checkpoint inhibitors (ICIs) and antiangiogenic agents is generally effective and well tolerated and might be effective for metastatic urothelial carcinoma (UC). However, ICI treatment is often associated with unique responses, such as pseudoprogression an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Zizhong, Zhang, Guoqing, Sun, Qiong, Liu, Minglu, Shao, Jiakang, Jiao, Shunchang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884808/ https://www.ncbi.nlm.nih.gov/pubmed/33604293 http://dx.doi.org/10.3389/fonc.2020.611810

Ejemplares similares

Nivolumab-Induced Pneumonitis in a Patient With Urothelial Cancer
por: Kasi, Arbab Furquan Ud din, et al.
Publicado: (2023)

Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
por: Melian, Marcos, et al.
Publicado: (2018)

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
por: Sweis, Randy F., et al.
Publicado: (2018)

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
por: Soria, Francesco, et al.
Publicado: (2018)

Relationship Between MUC4 Variants and Metastatic Recurrence in Colorectal Cancer
por: Liu, Jieqiong, et al.
Publicado: (2023)

Pilocytic Astrocytoma Enlargement Following Irradiation: Relapse or Pseudoprogression?
por: Trunin, Yury, et al.
Publicado: (2017)

Pseudoprogression after advanced first-line endocrine therapy in metastatic breast cancer with bone metastasis: A case report
por: Tian, Aijuan, et al.
Publicado: (2023)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Watanabe, Yukinobu, et al.
Publicado: (2021)

Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy– a report of two cases
por: Kolla, Bhaskar C., et al.
Publicado: (2016)

Ipilimumab/nivolumab: Immune-related pneumonitis: 2 case reports
Publicado: (2020)

Nivolumab: Interstitial pneumonitis: case report
Publicado: (2020)

Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma
por: Ikeda, Takaya, et al.
Publicado: (2018)

Cutaneous metastasis of bladder urothelial carcinoma
por: Hasan, Osamah, et al.
Publicado: (2019)

Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series
por: Xiang, Yongbo, et al.
Publicado: (2023)

Penile metastasis secondary to urothelial bladder cancer
por: Dolny, Maciej, et al.
Publicado: (2023)

Restriction Spectrum Imaging Differentiates True Tumor Progression From Immune-Mediated Pseudoprogression: Case Report of a Patient With Glioblastoma
por: Daghighi, Shadi, et al.
Publicado: (2020)

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report
por: Ozaki, Yukinori, et al.
Publicado: (2017)

A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer
por: Suyanto, Suyanto, et al.
Publicado: (2019)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Extracorporeal Membrane Oxygenation in Nivolumab Associated Pneumonitis
por: Schneider, Thomas-Michael, et al.
Publicado: (2017)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

5-Aminolevulinic Acid False-Positive Rates in Newly Diagnosed and Recurrent Glioblastoma: Do Pseudoprogression and Radionecrosis Play a Role? A Meta-Analysis
por: Ricciardi, Luca, et al.
Publicado: (2022)

Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis
por: Dumoulin, Daphne W., et al.
Publicado: (2020)

Nomogram for predicting survival in patients with advanced hepatocellular carcinoma treated with PD-1 inhibitors: incorporating pre-treatment and post-treatment clinical parameters
por: Jia, Guhe, et al.
Publicado: (2023)

Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)

Advanced Renal-Cell Carcinoma Pseudoprogression After Combined Immunotherapy: Case Report and Literature Review
por: Zhang, Xiaojie, et al.
Publicado: (2021)

Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report
por: Sarfaty, Michal, et al.
Publicado: (2017)

Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report
por: Yoshimura, Akihiro, et al.
Publicado: (2018)

Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma
por: Oliveira, Leandro J. C., et al.
Publicado: (2018)

Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment
por: Kumagai, Toru, et al.
Publicado: (2017)

Nivolumab for Metastatic Urothelial Cancer in a Renal Allograft Recipient With Subsequent Graft Rejection and Treatment Complete Remission: A Case Report
por: Chen, Didi, et al.
Publicado: (2021)

Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial
por: Stockem, C.F., et al.
Publicado: (2023)

Blood Biomarkers of Glioma in Response Assessment Including Pseudoprogression and Other Treatment Effects: A Systematic Review
por: Raza, Istafa J., et al.
Publicado: (2020)

Cutaneous metastasis of bladder urothelial carcinoma; A rare conditions
por: Öztürk, Hakan, et al.
Publicado: (2021)

Synovial Metastasis From Urothelial Carcinoma of the Renal Pelvis Causing Recurrent Hemarthrosis: A Rare Presentation
por: Wang, Rachel Tian Shian, et al.
Publicado: (2023)

Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events
por: Imafuku, Keisuke, et al.
Publicado: (2017)

A Case of Immune-Mediated Pneumonitis Associated With Dual Nivolumab and Ipilimumab Immunotherapy Treatment
por: Al-Saghir, Tala, et al.
Publicado: (2023)

Prostate cancer recurrence mimicking invasive urothelial cancer of the bladder
por: Okubo, Kazuki, et al.
Publicado: (2020)

The Diagnosis and Treatment of Pseudoprogression, Radiation Necrosis and Brain Tumor Recurrence
por: Parvez, Kashif, et al.
Publicado: (2014)

FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial
por: Damato, Angela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lrvl9bru2rr1h1etn82mmh3a7u